Stabilization of polymeric micelles with a mixed poly(ethylene oxide)/poly(2-hydroxyethyl methacrylate) shell by formation of poly(pentaerythritol tetraacrylate) nanonetworks within the micelles

2006 ◽  
Vol 16 (22) ◽  
pp. 2192-2199 ◽  
Author(s):  
Petar Petrov ◽  
Metodi Bozukov ◽  
Markus Burkhardt ◽  
Sharmila Muthukrishnan ◽  
Axel H. E. Müller ◽  
...  
RSC Advances ◽  
2014 ◽  
Vol 4 (66) ◽  
pp. 35027-35034 ◽  
Author(s):  
Yee Song Ko ◽  
Monica V. Circu ◽  
Thomas Geiger ◽  
Simon Dünki ◽  
Frank A. Nüesch ◽  
...  

A new poly(ethylene-co-butylene)-block-poly(ethylene oxide) surfactant was synthesized and used in inverse miniemulsion polymerization of 2-hydroxyethyl methacrylate with encapsulated Disperse Red 1.


2008 ◽  
Vol 41 (17) ◽  
pp. 6523-6530 ◽  
Author(s):  
Frédéric Renou ◽  
Lazhar Benyahia ◽  
Taco Nicolai ◽  
Otto Glatter

nano Online ◽  
2016 ◽  
Author(s):  
Runmiao Yang ◽  
Yanmei Wang ◽  
Dan Zhou ◽  
Jianyong Jia ◽  
Yanchun Han

2018 ◽  
Vol 21 (1s) ◽  
pp. 177s-191s ◽  
Author(s):  
Ziyad Binkhathlan ◽  
Raisuddin Ali ◽  
Wajhul Qamar ◽  
Afsaneh Lavasanifar

PURPOSE: The aim of this study was to assess the pharmacokinetics of methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micellar formulation of cyclosporine A (CyA) following oral administration in rats making comparisons with its commercial microemulsion formulation, Neoral®. METHODS: PEO-b-PCL copolymer was synthesized and used to form micelles encapsulating CyA. The release of CyA from Neoral® and PEO-b-PCL as well as PEO-b-PCL degradation were assessed in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). Polymeric micellar CyA and Neoral® were administered by oral gavage to healthy Wistar rats. At predetermined intervals, rats (n=5 for each time point) were euthanized, samples of blood and plasma were collected and analyzed for CyA using an LC-MS/MS assay. Blood and plasma pharmacokinetic parameters of CyA in its polymeric micellar formulation were compared to those of Neoral®. RESULTS: Polymeric micelles of CyA showed < 15 and 10% increase in diameter in SGF and SIF, respectively, within 24 h. PEO-b-PCL showed signs of minimal degradation when incubated for > 8 h in SGF, but was stable in SIF. Drug release in both SGF and SIF was comparable between the two formulations except for significantly higher release of CyA in SIF only at 24 h time point from Neoral®. Following oral administration (10 mg/kg), the blood AUC0-∞ and tmax of CyA in the polymeric micellar formulation was comparable to that for Neoral®. However, the Cmax of CyA-loaded PEO-b-PCL micelles was significantly (p < 0.05) higher than that obtained with Neoral® (2.10 ± 0.41 versus 1.40 ± 0.25 µg/mL, respectively). CyA had higher blood-to-plasma concentration ratios in polymeric micelles compared to Neoral®, in vivo. CONCLUSION: Our results show that PEO-b-PCL micelles can serve as stable and good solubilizing carriers for oral delivery of CyA providing similar pharmacokinetic profile to that of Neoral®.


Sign in / Sign up

Export Citation Format

Share Document